Network origin in Leif Rune Skymoen first degree
| Entity | Entity type | Industry | |
|---|---|---|---|
Curida AS
 Curida AS Pharmaceuticals: MajorHealth Technology Curida AS engages in the production of pharmaceutical products for other pharmaceutical companies, both in Norway and abroad. It manufactures and markets nasal and inhalation drug products. The company was founded in 1974 and is headquartered in Elverum, Norway.
1
| Holding Company | Pharmaceuticals: Major | 1 |
Chart of Companies connected to the second degree
Multi-company connection
Companies connected to Leif Rune Skymoen via their personal network
| Company | Sector | Related people | Main position |
|---|---|---|---|
Oslo Cancer Cluster NCE
 Oslo Cancer Cluster NCE Miscellaneous Commercial ServicesCommercial Services Oslo Cancer Cluster NCE is an oncology research firm that specializes in developing cancer diagnostics and medicines. The private company is based in Oslo, Norway. | Miscellaneous Commercial Services | Chairman | |
| AstraZeneca AS | Corporate Officer/Principal | ||
| University of Oslo | College/University | Doctorate Degree | |
| Boehringer Ingelheim Norway KS | Chief Tech/Sci/R&D Officer | ||
| ULTIMOVACS ASA | Pharmaceuticals: Major | Chief Executive Officer | |
| Bristol-Myers Squibb Norway Ltd. | Chief Tech/Sci/R&D Officer | ||
Cytovation AS
 Cytovation AS Miscellaneous Commercial ServicesCommercial Services Cytovation AS is a Norwegian clinical stage immune-oncology company that focuses on developing Cypep-1, a first-in-class immunotherapy that targets the cell membrane of tumor cells. The company is a spin-off from the University of Bergen and is headquartered in Bergen, Norway. Cypep-1 has a unique mechanism of action that eliminates cancer cells by forming pores in the plasma membrane, releasing antigens to the immune system, promoting an inflammatory microenvironment, and inducing a tumor-specific immune response by in situ vaccination. Cytovation develops treatments for solid tumors in oncology and rare diseases, building on over 15 years of cutting-edge research. The CEO is Lars Prestegarden, and the company was founded by Rolf Bjerkvig, Per Eystein, and Stein Christian Mohn. | Miscellaneous Commercial Services | Director/Board Member | |
| VITMED AS | Chief Executive Officer | ||
Hubro Therapeutics AS
 Hubro Therapeutics AS BiotechnologyHealth Technology Hubro Therapeutics AS develops and trades biomedical products and services. It offers a technology platform for cancer vaccines targeting stomach and colon cancer. The company was founded by Jon Amund Eriksen on November 20, 2018 and is headquartered in Oslo, Norway. | Biotechnology | Chairman |
Statistics
International
| Norway | 10 |
Sectoral
| Commercial Services | 3 |
| Health Technology | 3 |
| Consumer Services | 2 |
Operational
| Director/Board Member | 4 |
| Chairman | 3 |
| Chief Executive Officer | 2 |
| Chief Tech/Sci/R&D Officer | 2 |
| Investor Relations Contact | 1 |
Most connected contacts
| Insiders | |
|---|---|
| Øyvind Kongstun Arnesen | 10 |
- Stock Market
- Insiders
- Leif Rune Skymoen
- Company connections
